Kymera gains FDA Fast Track for KT-621 as Gilead licenses KT-200
Kymera said the FDA granted Fast Track designation to KT-621 for moderate to severe eosinophilic asthma, while Gilead licensed KT-200 and triggered a $45 million milestone payment.
Kymera
CompanyAlso known as: Kymera
Related News
Drug Hunter's Most Popular Content of 2025 Highlights Industry Trends
Drug Hunter's most-accessed resources, reviews, and case studies in 2025 reflected key trends in drug discovery, including the rise of oral macrocycles, advances in new modalities, and the shift from biologics to small molecules in immunology.
Drug Discovery Patent Filings Span Protein Degradation, Ion Channels, and Emerging Targets
Monthly patent reviews from April through December 2025 highlight notable drug discovery IP disclosures across targeted protein degradation, small molecule modulators, and emerging therapeutic targets in oncology, immunology, and neurology.